Oncology Unit


HPL has established a world class, state-of-the-art and dedicated Oncology manufacturing unit with high-containment processing and testing facility (with 100% Isolators) under consultancy support by an Australian company (APC) for the manufacture and supply of oral solids & injectable products for both local and international markets.

Our major production machineries are from world reputed sources like Steriline-Italy, TF-120-Italy, Zirbus-Germany, O’Hara-Canada, GEA-Belgium, etc. All production machines for solid and sterile operate under OEB-5 Containment compliant with 21 CFR. OEB-5 Containment is strictly followed at every critical stage of operations to ensure safety of people, protection of the environment and avoidance of product contamination.

The site is now under quality surveillance of global reputed Lachman Consultant -USA, and ready to offer a new Onco-facility for interested partners in business in US markets.

Full containment Gowning

HPL established the highest level of full containment process Occupational Exposure Limit OEB Level 5, Steriline, Italy which ensures airlock access, unidirectional airflow and process containment-gowning.

HPL assuring world class full containment process in all stages of operations guided by Isolated & Controlled Manufacturing Technology, Safe Sampling & Analysis Technology and High End Microbiology Testing Facilities.

Research & Development

Our R & D team is engaged in a well-defined program with a primary focus on the Novel drug delivery system. Quality-by-Design (QbD) Driven Development provides robust manufacturing, science-based process limits and assurance of Quality Attributes within the control space. QbD Construct Quality Target Profile (QTPP) as well as identify & confirm the Critical Quality Attributes (CQAs).

We strive to advance the frontiers of cancer therapy producing high-impact medicines for cancer patients.

Our Product Portfolio

HPL Oncology is committed to developing transformative therapies that improve the outlook for cancer patients worldwide.

Our product portfolio—one of the most robust in the industry—includes Tablets, Injectable, Lyophilized Vial, Biologic, Biosimilar, with a strong list of products under development. We seek to translate the most innovative science into meaningful breakthrough medicines that re-define life of cancer patients.